Oryzon Genomics: Alzheimer aid

Barcelona-based epigenetics specialist Oryzon Genomics has made new additions to its Scientific Advisory Board in order to be prepared for the completion of its Phase I trial for dementia drug ORY-2001. Renowned Alzheimer’s disease expert Howard Fillit will take over a seat on the board.

ADVERTISEMENT

Fillit is the Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. He is also a clinical professor of geriatric medicine and palliative care, medicine, and neurosciences at The Icahn School of Medicine at Mount Sinai Medical Center, New York. Fillit has held faculty positions at Rockefeller University, SUNY-Stony Brook School of Medicine, and Cornell University School of Medicine,  and has more than 300 scientific publications to his name. Together with Fillit, neurologist José Luis Molinuevo, Scientific Director of the Barcelonabeta Brain Research Center of the Pasqual Maragall Foundation, will also join Oryzon’s ­Scientific Advisory Board.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!